Nuvation Bio Inc.
NUVB- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001811063
In the last 90 days, Nuvation Bio Inc. insiders filed 0 open-market purchases and 1 sale; 244 institutions reported holding it in 13F filings for Q2 2026, worth $1.33B in total; 3 superinvestors hold it, including Duquesne Family Office and Abrams Capital.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Nuvation Bio Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 1 filing
- 1 insider, $709.2K in total
- Insiders trading
- 1
- Net value
- −$709.2K
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Nuvation Bio Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Hattersley Gary | CHIEF SCIENTIFIC OFFICER | 0 | Aug 21, 2026 | 4 |
| Sauvage Philippe | Chief Financial Officer | 54,131 | Jul 17, 2026 | 3 |
| Wentworth Kerry | CHIEF REGULATORY OFFICER | 53,000 | Jun 24, 2026 | 4 |
| Markel Stacy | CHIEF PEOPLE OFFICER | 32,591 | Jun 24, 2026 | 2 |
| Mashal Robert | Director | 225,000Indirect | Jun 11, 2026 | 2 |
| Falberg Kathryn E | Director | 250,000Indirect | May 26, 2026 | 1 |
| Blickenstaff Kim D | Director | 172,189Indirect | May 26, 2026 | 1 |
| Vernon W Anthony | Director | – | May 26, 2026 | 1 |
| Cui Xiangmin | Director | 17,062,202Indirect | May 26, 2026 | 2 |
| Bazemore Robert B | Director | – | May 26, 2026 | 1 |
| Liu Dongfang | CHIEF MEDICAL OFFICER | 18,000 | Apr 21, 2026 | 6 |
| Hung David | PRESIDENT AND CEO | 59,281,054 | Mar 3, 2026 | 1 |
| Hanley David C. | CHIEF TECHNICAL OPERATIONS | 24,000 | Mar 3, 2026 | 2 |
| Makunje Moses | SEE REMARKS | 68,137 | Mar 3, 2026 | 1 |
| Sjogren Colleen | Chief Commercial Officer | 81,000 | Mar 3, 2026 | 1 |
| Wang Junyuan Jerry | CEO, ANHEART THERAPEUTICS LTD. | 3,866,228 | Nov 13, 2024 | 0 |
| Welch Daniel G | Director | 659,947 | May 29, 2024 | 0 |
| Nodelman Oleg | Director | 12,674,775Indirect | Sep 22, 2023 | 0 |
| EcoR1 Capital Fund, L.P. | Director | 12,674,775Indirect | Sep 22, 2023 | 0 |
| EcoR1 Capital, LLC | Director | 12,674,775Indirect | Sep 22, 2023 | 0 |
| EcoR1 Capital Fund Qualified, L.P. | Director | 12,674,775Indirect | Sep 22, 2023 | 0 |
| EcoR1 Venture Opportunity Fund, LP | Director | 12,674,775Indirect | Sep 22, 2023 | 0 |
| Biotech Opportunity GP, LLC | Director | 12,674,775Indirect | Sep 22, 2023 | 0 |
| Fox Jennifer A. | Chief Financial Officer | – | Mar 2, 2023 | 0 |
| Omega Fund V GP Manager, Ltd. | 10% Owner | 20,457,340 | Apr 7, 2022 | 0 |
| Omega Fund V, L.P. | 10% Owner | 20,457,340 | Apr 7, 2022 | 0 |
| Omega Fund V GP, L.P. | 10% Owner | 20,457,340 | Apr 7, 2022 | 0 |
| Omega Fund IV GP, L.P. | 10% Owner | 22,957,340 | Dec 17, 2021 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Aug 21, 2026 (view filing)4:49 PM ET | Aug 19 | 2 days | Hattersley GaryCHIEF SCIENTIFIC OFFICER | SSaleClass A Common Stock | −100.0K | $7.09 | −$709.2K | −100.0%0 after | 10b5-1 |
| Jun 24, 2026 (view filing) | Jun 23 | 1 day | Sauvage PhilippeChief Financial Officer | SSaleClass A Common Stock | −47.7K | $6.01 | −$286.5K | −79.0%12.7K after | 10b5-1 |
| Jun 24, 2026 (view filing) | Jun 23 | 1 day | Markel StacyCHIEF PEOPLE OFFICER | SSaleClass A Common Stock | −125.0K | $6.03 | −$753.8K | −79.3%32.6K after | 10b5-1 |
| Jun 24, 2026 (view filing) | Jun 23 | 1 day | Wentworth KerryCHIEF REGULATORY OFFICER | SSaleClass A Common Stock | −63.0K | $6.02 | −$379.3K | −54.3%53.0K after | 10b5-1 |
| Jun 11, 2026 (view filing) | Jun 9 | 2 days | Mashal RobertDirector | PPurchaseClass A Common Stock | +25.0K | $4.73 | +$118.3K | +12.5%225.0K after | |
| Apr 21, 2026 (view filing) | Apr 17 | 4 days | Liu DongfangCHIEF MEDICAL OFFICER | SSaleClass A Common Stock | −50.0K | $5.02 | −$251.0K | −73.5%18.0K after | 10b5-1 |
| Apr 21, 2026 (view filing) | Apr 17 | 4 days | Wentworth KerryCHIEF REGULATORY OFFICER | SSaleClass A Common Stock | −36.8K | $5.01 | −$184.1K | −40.9%53.0K after | 10b5-1 |
| Apr 8, 2026 (view filing) | Apr 6 | 2 days | Wentworth KerryCHIEF REGULATORY OFFICER | SSaleClass A Common Stock | −200.0K | $4.52 | −$904.0K | −79.1%53.0K after | 10b5-1 |
| Dec 3, 2025 (view filing) | Dec 1 | 2 days | Liu DongfangCHIEF MEDICAL OFFICER | SSaleClass A Common Stock | −150.0K | $7.82 | −$1.17M | −89.3%18.0K after | |
| Nov 26, 2025 (view filing) | Nov 25-26 | 1 day | Liu DongfangCHIEF MEDICAL OFFICER | SSaleClass A Common Stock | −20.0K | $7.75 | −$155.0K | −52.6%18.0K after | 2 lots |
| Nov 24, 2025 (view filing) | Nov 20 | 4 days | Liu DongfangCHIEF MEDICAL OFFICER | SSaleClass A Common Stock | −20.0K | $7.00 | −$140.0K | −52.6%18.0K after | |
| Nov 24, 2025 (view filing) | Nov 20 | 4 days | Hattersley GaryCHIEF SCIENTIFIC OFFICER | SSaleClass A Common Stock | −369.1K | $7.23 | −$2.67M | −100.0%0 after | 2 lots |
| Nov 21, 2025 (view filing) | Nov 19 | 2 days | Hanley David C.CHIEF TECHNICAL OPERATIONS | SSaleClass A Common Stock | −200.0K | $7.14 | −$1.43M | −89.3%24.0K after | |
| Nov 19, 2025 (view filing) | Nov 17-19 | 2 days | Liu DongfangCHIEF MEDICAL OFFICER | SSaleClass A Common Stock | −30.0K | $4.94 | −$148.1K | −62.5%18.0K after | 2 lots |
| Oct 29, 2025 (view filing) | Oct 27 | 2 days | Hattersley GaryCHIEF SCIENTIFIC OFFICER | SSaleClass A Common Stock | −100.0K | $5.02 | −$502.0K | −100.0%0 after | 10b5-1 |
| Jun 18, 2025 (view filing) | Jun 18 | Same day | Markel StacyCHIEF PEOPLE OFFICER | PPurchaseClass A Common Stock | +10.0K | $1.71 | +$17.1K | +51.0%29.6K after | |
| Jun 18, 2025 (view filing) | Jun 16-17 | 2 days | Sauvage PhilippeChief Financial Officer | PPurchaseClass A Common Stock | +7.30K | $1.81 | +$13.2K | +280.6%9.90K after | 2 lots |
| Jun 18, 2025 (view filing) | Jun 16 | 2 days | Sjogren ColleenChief Commercial Officer | PPurchaseClass A Common Stock | +50.0K | $1.81 | +$90.5K | +161.3%81.0K after | |
| Jun 18, 2025 (view filing) | Jun 16 | 2 days | Wentworth KerryCHIEF REGULATORY OFFICER | PPurchaseClass A Common Stock | +50.0K | $1.79 | +$89.7K | New position50.0K after | 2 lots |
| Jun 18, 2025 (view filing) | Jun 16 | 2 days | Hung DavidPRESIDENT AND CEO | PPurchaseClass A Common Stock | +500.0K | $1.79 | +$895.0K | +0.9%59.3M after | |
| May 6, 2025 (view filing) | May 2 | 4 days | Liu DongfangCHIEF MEDICAL OFFICER | SSaleClass A Common Stock | −20.0K | $2.50 | −$50.0K | −62.5%12.0K after | 10b5-1 |
| Apr 8, 2025 (view filing) | Apr 4-7 | 4 days | Hung DavidPRESIDENT AND CEO | PPurchaseClass A Common Stock | +500.0K | $1.64 | +$821.0K | +0.9%58.8M after | 2 lots |
| Apr 3, 2025 (view filing) | Apr 1 | 2 days | Mashal RobertDirector | PPurchaseClass A Common Stock | +100.0K | $1.67 | +$167.0K | +100.0%200.0K after | 2 lots |
| Nov 13, 2024 (view filing) | Nov 11 | 2 days | Wang Junyuan JerryCEO, ANHEART THERAPEUTICS LTD. | SSaleClass A Common Stock | −56.4K | $2.89 | −$162.9K | −1.4%3.87M after | |
| Oct 10, 2024 (view filing) | Oct 8 | 2 days | Mashal RobertDirector | PPurchaseClass A Common Stock | +100.0K | $2.20 | +$220.0K | New position100.0K after | 2 lots |
| Jun 26, 2024 (view filing) | Jun 25 | 1 day | Cui XiangminDirector | PPurchaseClass A Common Stock | +277.9K | $2.97 | +$825.3K | +12.8%2.45M after | |
| Jun 25, 2024 (view filing) | Jun 20-24 | 5 daysLate | Cui XiangminDirector | PPurchaseClass A Common Stock | +500.0K | $2.98 | +$1.49M | +29.8%2.18M after | 3 lots |
| Jun 13, 2024 (view filing) | Jun 11 | 2 days | Blickenstaff Kim DDirector | PPurchaseClass A Common Stock | +172.2K | $2.90 | +$499.3K | New position172.2K after | |
| Sep 22, 2023 (view filing)3:44 PM ET | Sep 19-21 | 3 days | Nodelman Oleg and 5 othersDirector | PPurchaseClass A Common Stock | +5.31M | $1.26 | +$6.69M | +72.2%12.7M after | Amended3 lots |
| Dec 5, 2022 (view filing) | Nov 30-Dec 5 | 5 daysLate | Falberg Kathryn EDirector | PPurchaseClass A Common Stock | +250.0K | $1.93 | +$483.1K | New position250.0K after | 4 lots |
| Apr 7, 2022 (view filing)4:52 PM ET | Apr 5 | 2 days | Omega Fund V GP Manager, Ltd. and 2 others10% Owner | SSale | −2.50M | $5.60 | −$14.0M | −10.9%20.5M after | |
| Dec 17, 2021 (view filing)5:13 PM ET | Dec 15 | 2 days | Omega Fund IV GP, L.P. and 2 others10% Owner | SSale | −500.0K | $10.07 | −$5.04M | −2.1%23.0M after | |
| Dec 9, 2021 (view filing)3:59 PM ET | Dec 7 | 2 days | Omega Fund V GP Manager, Ltd. and 2 others10% Owner | SSale | −1.40M | $9.80 | −$13.7M | −5.6%23.5M after | |
| Nov 30, 2021 (view filing)6:07 PM ET | Mar 31-Nov 24 | 244 daysLate | Nodelman Oleg and 5 othersDirector | PPurchaseClass A Common Stock | +393.2K | $8.89 | +$3.49M | +50.7%1.17M after | 4 lots |
| Nov 30, 2021 (view filing)6:07 PM ET | Mar 31 | 244 daysLate | Nodelman Oleg and 5 othersDirector | SSaleClass A Common Stock | +151.5K | $10.45 | +$1.58M | +15.2%1.15M after | |
| Nov 30, 2021 (view filing)6:07 PM ET | Jul 31 | 122 daysLate | Nodelman Oleg and 5 othersDirector | SSaleClass A Common Stock | −56.6K | $8.64 | −$489.0K | −4.7%1.15M after | |
| Nov 24, 2021 (view filing)6:38 PM ET | Nov 22-23 | 2 days | Omega Fund V GP Manager, Ltd. and 2 others10% Owner | SSale | −295.0K | $9.76 | −$2.88M | −1.2%24.9M after | 2 lots |
| Nov 5, 2021 (view filing)5:31 PM ET | Nov 3 | 2 days | Omega Fund V GP Manager, Ltd. and 2 others10% Owner | SSale | −2.00M | $9.25 | −$18.5M | −7.4%25.2M after | |
| Nov 1, 2021 (view filing)5:01 PM ET | Oct 28-29 | 4 days | Omega Fund V GP Manager, Ltd. and 2 others10% Owner | SSale | −1.06M | $9.59 | −$10.2M | −3.8%27.2M after | 2 lots |